Janssen-Cilag International N.V

Company snapshot

Janssen-Cilag International N.V maintains 161 tracked programs across Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions, Moderately to Severely Active Crohn's Disease, Moderate to Severe Plaque Psoriasis, Moderately to Severely Active Ulcerative Colitis, Relapsed or Refractory Multiple Myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia, Active Psoriatic Ar

• 161 active pipeline program(s) linked via ClinicalTrials.gov.
• 161 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Janssen-Cilag International N.V. Not investment advice.

• approval Jun 11, 2026

  FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria

• Peer + 0 momentum

  Bristol-Myers Squibb Australia

  TA overlap score 38.6

• Peer + 0 momentum

  Celgene

  TA overlap score 29

• Peer + 0 momentum

  Nanjing Legend Biotech

  TA overlap score 27.2

• Peer + 0 momentum

  Kyowa Kirin International

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Janssen-Cilag International N.V.

1. Jun 8, 2026 Clinical update

   90014496LYM1001 — Phase 1

2. Jun 8, 2026 Clinical update

   87189401PCR1001 — Phase 1

3. Jun 8, 2026 Clinical update

   77242113PSO3003 — Phase 3

4. Jun 8, 2026 Clinical update

   77242113PSO3001 — Phase 3

5. Jun 8, 2026 Clinical update

   64407564MMY1004 — Phase 1

View all clinical trial activity →

• What is Janssen-Cilag International N.V?

  Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions, Moderately to Severely Active Crohn's Disease, Moderate to Severe Plaq

• Is Janssen-Cilag International N.V publicly traded?

  Janssen-Cilag International N.V appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Janssen-Cilag International N.V develop or market?

  We link 159 drug profile(s) where Janssen-Cilag International N.V is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/janssen-cilag-international-n-v#company-drugs.

• What are the latest developments for Janssen-Cilag International N.V?

  In the last 12 months our linked public records show 161 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Janssen-Cilag International N.V focus on?

  Janssen-Cilag International N.V focuses on Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions based on our analysis of their pipeline programs and drug development activities.